menu
    • menu

    Company profile for EUROAPI

    EUROAPI-PSE
    News
    Tristan Imbert Co-Opted As Independent Director

    10 Dec 2025

    // PRESS RELEASE

    EUROAPI Boosts Pharmaceutical Innovation With Med4Cure

    23 Oct 2025

    // PRESS RELEASE

    Abolis Bio, EUROAPI Partner to Boost Pharma Innovation in Europe

    23 Oct 2025

    // BUSINESSWIRE

    DATA COMPILATION
    #PharmaFlow

    EUROAPI VB

    Contact Supplier

    Website

    Global ChemShow

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/a6j54hn1CIE

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Related CompaniesRelated Companies

    About

    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EUROAPIFrance Flag
    Country
    Country
    France
    Address
    Address
    15 rue Traversière , 75012 Paris
    Telephone
    Telephone
    +33 189206200
    Client Email
    Email
    contact@euroapi.com
    Client Website
    Website
    https://www.euroapi.com/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/euroapi/
    youtube
    YouTube
    http://www.youtube.com/@euroapi3005
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-80011.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-59745.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediate Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-57505.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Products Under Development 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-4583.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-98791.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Acquisition of BianoGMP to Strengthen Oligonucleotide Market

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-12498.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Restart of Prostaglandin Production at Budapest Site

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-66592.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Peptide & Oligonucleotide Capacity to reach 500 kg/year by 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-70684.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    EUROAPI to invest €40 million for Vitamin B12 production

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-26109.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Listing on Euronext Paris

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-1652083459.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    EUROAPI meets all conditions for its listing on Euronext Paris

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-1651646035.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    French AMF Approval for Euronext Paris Listing

    read-more

      https://www.pharmacompass.com/pdf/party/content/euroapi-party-content-1649243874.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3083

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share
    Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

    Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

    Precise particle size control has become the cornerstone of modern pharmaceutical manufacturing. With highly potent active pharmaceutical ingredients (HPAPIs) and complex formulations driving unprecedented demand, micronization technology is no longer optional — it's critical. The market reflects this urgency. The global API micronization market will jump from US$ 2.47 billion in 2024 to US$ 3.68 billion by 2030 — a 49 percent surge driven by a robust 6.84 percent CAGR. What's powering this growth? Strategic innovation by industry leaders. Companies like Munit SA, Lonza, Catalent, Veranova, EUROAPI, AGC Pharma Chemicals, Hovione and Coral Drugs aren't just participating — they're defining the future of pharmaceutical particle engineering. The Micronization Landscape: How leading companies are advancing pharmaceutical particle engineering The API micronization space is being shaped by companies with specialized expertise. Munit’s proprietary fluid jet milling technology brings particle sizes down to the 1-micron level — critical for inhalation therapies. In addition, this technology enables precise control over particle size distribution without mechanical impact, making it ideal for heat-sensitive and high-potency APIs. With decades of hands-on experience, Munit ensures batch-to-batch consistency, scalability from R&D to commercial volumes, and full compliance with GMP standards.  Munit offers high-containment isolators — including glove boxes for R&D and half-suit isolators for larger batches — with industry-leading containment levels, limiting airborne drug exposure to as low as 0.025 micrograms per cubic meter. This makes it particularly well-suited for handling highly potent or sensitive compounds, exceeding the capabilities of other commercial-scale players like Catalent, who typically achieve containment levels of 0.05 micrograms per cubic meter or higher. EUROAPI has taken a broad particle engineering approach, offering both micronization and spray drying across multiple dosage routes — oral, inhaled, and parenteral. AGC Pharma Chemical leverages spray drying and amorphous solid dispersion technologies across small molecules, peptides, ADCs, and oligonucleotides, exemplifying the evolving intersection of particle engineering and modern drug delivery innovation. Coral Drugs delivers cutting-edge technology and customization capabilities that tailor particle sizes to specific client requirements across tablets, injectables, and topicals. This dynamic competitive landscape continues to evolve as companies expand capabilities and form strategic partnerships. This year, Dec Group announced the launch of their cutting-edge Micronization Suite, now operational in Brick, New Jersey, while Lonza joined the Centre for Continuous Manufacturing and Advanced Crystallisation, an international research hub, to develop innovative continuous processing and crystallization solutions. Selecting the right micronization partner: Key success factors In a pharmaceutical landscape increasingly defined by complexity, precision, and speed-to-market, the choice of a micronization partner can significantly influence a drug’s success. Among the players in this space, Munit SA has emerged as a trusted and strategic ally for pharmaceutical companies worldwide. But what exactly sets Munit apart in the micronization market? To begin with, Munit SA brings over 60 years of experience in particle size engineering. This legacy is not just a number; it reflects decades of accumulated knowledge, process refinement, and a deep understanding of how particle size impacts drug performance. In an industry where even minor deviations can compromise efficacy or safety, this level of experience is invaluable. It has delivered over 500 successful micronization projects to more than 150 customers globally. At its core, Munit SA is laser-focused on micronization and milling — not as ancillary services, but as its primary mission. Their facilities are designed for processing high-potency APIs, cytotoxic and cytostatic compounds, non-beta-lactam antibiotics, steroids, and controlled substances under stringent containment protocols. The company also handles inhalation products, peptides, biological drugs, generics, and R&D compounds. Whether it's micronization for ophthalmic formulations, transdermal or oral products, Munit offers a tailored approach. It stands as a world-leading provider of micronization services in inhalation powders with particle sizes of 1-5 microns and specialized oncology applications for small molecules. In an increasingly complex global landscape, Munit SA addresses supply chain challenges through its dual-site operational model, with facilities in Switzerland (Jetpharma SA) and Italy (Microchem S.r.l). This strategic setup mitigates risks from regulatory changes, geopolitical tensions, or environmental disruptions, ensuring continuous production and delivery of critical APIs. This resilience makes Munit a trusted partner for companies prioritizing business continuity. Why pharmaceutical companies choose Munit for advanced micronization and milling Munit’s proprietary MC Jet Mill is a testament to its engineering excellence. For heat-sensitive APIs, Munit’s cryogenic micronization process uses liquid nitrogen to cool materials, preventing thermal degradation and preserving the integrity of delicate molecules. This is particularly valuable for biologics and APIs with low melting points, where stability is paramount. Additionally, Munit’s under containment micronization employs advanced systems to safely handle HPAPIs, protecting both operators and the environment while meeting stringent regulatory standards.  Their co-micronization service, which processes APIs alongside excipients, further enhances formulation stability and solubility, offering innovative solutions for complex drug profiles. These capabilities, executed under Good Manufacturing Practices (GMP), make Munit a reliable choice for pharmaceutical companies seeking precision and quality. While micronization is Munit’s flagship, it offers milling services through an array of technologies, each suited to specific needs. The Pin Mill uses a grinding chamber and particle size reduction is achieved due impact against a high-speed pin rotor, producing sizes from 50 to 150 microns. It’s particularly effective for APIs needing improved flow for tableting, offering precise size control that ensures uniformity. The Quadro Co-Mill excels at soft de-lumping and homogenization, using a conical sieve and impeller to gently process powders without altering primary particle sizes. For tougher materials, the HammerMill C-10 employs hammer bars on a rotor to crush particles. State-of-the-Art Particle Engineering: Munit's strategic innovation push delivers next-gen solutions Munit’s leadership in micronization is underpinned by a deliberate and sustained investment in innovation — aimed at building the next generation of particle size engineering. In response to client challenges with condensation and product degradation, Munit developed a proprietary conditioning system that precisely controls humidity and temperature. Engineered with ergonomic design and fluid dynamics principles, their machine represents a qualitative leap in conditioning. Munit's new AIFA-approved Building C transforms the Italian hub's capacity. Equipped for high potent, toxic, cytotoxic, and cytostatic compounds, alongside hormones, it features cutting-edge safety systems and integrated technologies, enabling broader API processing with precision and compliance. Munit has merged quality assurance and regulatory affairs into one strategic unit, streamlining workflows and enhancing client responsiveness during critical validation phases. This delivers tailored regulatory support and accelerates time-to-market. These initiatives position Munit at the forefront of particle size engineering, where state-of-the-art innovation, regulatory excellence, and client-centric design converge to set new industry standards. Our view The API micronization market is projected to grow 49 percent to US$ 3.68 billion by 2030. In this evolving landscape, companies that combine deep technical expertise with operational resilience are positioned to capture the greatest value. Munit SA exemplifies this winning formula.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 7750

    https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers

    #Phispers by PHARMACOMPASS
    10 Sep 2025
    Share Share
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 8683

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. While this trend continued into 2024, the industry showed signs of stabilization in the last four months of the year with the pace of layoffs slowing down. Nonetheless, 2024 was a challenging year. Data compiled by PharmaCompass indicates that over 25,000 layoffs were announced in 2024, driven by economic pressures, failed clinical trials, and strategic pivots. Bristol Myers Squibb and Johnson & Johnson led the layoffs with about 2,300 job cuts each. Bayer announced elimination of 1,800 positions.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available) US, Europe, China bear brunt of job cuts; Big Pharma hands pink slips to 10,000 Over 190 biopharma companies announced layoffs in 2024. The year began on a grim note — 27 firms announced significant job cuts in January 2024. By the yearend, Big Pharma alone had contributed more than 10,000 layoffs to the year’s total of over 25,000. Novartis announced over 1,200 job cuts in 2024. It eliminated 330 jobs after it acquired German biotech MorphoSys through the closure of sites in Munich and Boston. Similarly, Bayer announced significant reductions at its US and Swiss facilities.  North America saw increased retrenchments, especially at biotech hubs such as Boston, San Diego, and New Jersey. Massachusetts, with Boston and Cambridge as the epicenter of US biotechnology, saw around 4,000 layoffs, with companies like Relay Therapeutics, Editas Medicine, and Takeda driving the numbers. In San Diego, workforce reductions by Takeda, and Bavarian Nordic collectively resulted in over 900 job losses, significantly impacting the local biotech ecosystem. New Jersey was subject to broader restructuring efforts with BMS and Bayer contributing nearly 1,500 layoffs. The impact in Europe was equally severe. Germany, home to some of the world’s largest pharmaceutical companies, saw over 2,500 layoffs as Bayer and Boehringer Ingelheim scaled back operations. Novartis’ decision to shut down its Munich site added hundreds more to the tally. In Switzerland, Idorsia eliminated 270 positions. Dutch biotech UniQure reduced its workforce by 65 percent (around 300 jobs). That included the sale of a Massachusetts manufacturing facility to Genezen. Denmark also felt the strain, with Leo Pharma cutting 250 roles as part of a strategic revamp. China emerged as another focal point of workforce reductions in 2024. Global pharmaceutical giants, such as Merck and Johnson & Johnson, restructured their operations in response to market complexities in the region. Local companies such as Connect Biopharma, which is transitioning to a US-focused company, also scaled back their presence in the country.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Amylyx, FibroGen, Lyra, Athira drastically reduce staff over setbacks in clinical trials Clinical trial failures were one of the most significant drivers of layoffs in 2024. For instance, Amylyx Pharmaceuticals faced a devastating blow when its amyotrophic lateral sclerosis (ALS) therapy, Relyvrio, failed a confirmatory trial. This led to a 70 percent reduction in its workforce, leaving only 100 employees from the 384 full-time staff reported at the end of 2023. The company’s decision to pull the therapy from the market compounded the layoffs. BioMarin Pharmaceutical had to reduce its workforce, as it streamlined its pipeline in response to trial challenges. In August, the company announced a reduction of 225 employees, citing “organizational redesign efforts”. These layoffs followed 170 redundancies announced earlier in May. FibroGen, once considered a leader in oncology drug development, was among the most heavily impacted. The high-profile failure of its anti-CTGF antibody in two late-stage cancer trials led to the discontinuation of its lead candidate, resulting in a 75 percent reduction in its US workforce. Lyra Therapeutics also implemented a 75 percent workforce reduction, affecting 87 employees, after its chronic rhinosinusitis program struggled. Similarly, Athira Pharma cut 70 percent of its team after its Alzheimer’s candidate failed a phase 2/3 trial.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Cash crunch, mergers compel Kronos Bio, Editas, Vincerx, Gilead to downsize In addition to clinical failures, funding constraints played a pivotal role in reshaping the biotech landscape. Kronos Bio stood out as one of the hardest-hit firms, cutting 21 percent and 83 percent of its existing workforce in March and November, respectively, as it sought to divest assets and conserve cash. Editas Medicine’s inability to secure partnerships for its sickle cell program forced the company to revert to preclinical research, resulting in a 65 percent workforce reduction. The trend of scaling back R&D pipelines was particularly evident among biotechs struggling to advance preclinical programs to clinical trials. Boundless Bio and Senti Bio exemplified this, choosing to focus on a handful of promising candidates, while reducing discovery efforts. Consolidation often results in overlapping roles, leading to inevitable workforce reductions. Apart from the MorphoSys layoffs by Novartis, Vincerx Pharma faced job losses after it got acquired by Oqory (a clinical-stage ADC company). Vincerx had to cut its workforce by 55 percent.  Amid ongoing reorganization efforts, Gilead closed its Seattle, Washington (US), office and laid off 72 employees of its subsidiary Kite Pharma. Gilead also announced that its Kite facility in Philadelphia, Pennsylvania (US), would close by mid-2025. That was followed by 104 additional layoffs at its California headquarters. In April, it had cut 58 jobs in California. Gilead also announced that its Kite facility in Philadelphia would close by mid-2025. Vir Biotechnology reduced its workforce by 25 percent (i.e. 140 layoffs) to focus on its hepatitis program, and GlycoMimetics let go of 80 percent of its workforce after the FDA demanded an additional clinical trial for its leukemia treatment. Meanwhile, Lexicon Pharmaceuticals reduced its workforce by 60 percent after it stopped commercial operations and transitioned back to being a clinical stage company.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Our view It takes decades to build innovation ecosystems. The concentration of layoffs in major biotech hubs has raised concerns about the potential long-term impact on these ecosystems. In 2025, the key challenge will be to maintain the momentum of innovation, as organizations operate with a leaner workforce and a more focused pipeline.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 7617

    https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch

    #PharmaFlow by PHARMACOMPASS
    16 Jan 2025
    Share Share
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4597

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 14788

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share
    US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains

    US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains

    Over the last few decades, the United States and Europe have saved trillions of dollars by importing drugs from countries like China and India. Their journey wasn’t easy, with regulatory non-compliance and drug patent scams raising their ugly heads every now and then. The Covid-19 pandemic and the accompanying lockdowns were a wake-up call for these countries to take a long, hard look at their sourcing strategies.Over the last few years, both the US and Europe have embarked on policy changes and ambitious programs to strengthen their drug supply chains. PharmaCompass takes you through US and Europe’s journeys towards more robust pharmaceutical supply chains.Biden’s executive order, CARES Act, state-backed investments strengthen US supply chainDuring the early days of the pandemic, the US government (under former President Donald Trump)  had enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to address the economic fallout of the pandemic through a US$ 2.2 trillion stimulus. Through this act, the FDA had taken several drug shortage mitigation efforts. The new administration under President Joe Biden undertook more measures. Notable amongst them was Executive Order 14017 on America’s supply chains. It mandated a comprehensive 100-day review to identify vulnerabilities in key sectors, including pharmaceuticals and active pharmaceutical ingredients (APIs). The review noted that 87 percent of generic API facilities are located overseas, leaving the US healthcare system vulnerable to shortages of essential medicines.Through a Presidential Determination, Biden had also broadened US Department of Health and Human Services’ (HHS) authorities under the Defense Production Act (DPA) of 1950. HHS can now enable investment in domestic manufacturing of essential medicines and medical countermeasures under the DPA. The HHS has invested US$ 17 billion in domestic manufacturing for the medical supply chain, including US$ 500 million to support API manufacturing.Under this effort, Merck has been awarded a €121 million (US$ 132 million) government contract to set up a lateral flow membrane production facility at Sheboygan, Wisconsin. Similarly, California has launched an initiative (known as CalRx) and is working with CIVICA to make US$ 30 insulin available to all who need it.Europe encourages reshoring; EDQM develops monographs for unlicensed alternativesIn recent years, Europe has faced shortages of insulin, antibiotics, oncology drugs, corticosteroids and even paracetamol. To overcome these shortages, the European Medicines Agency (EMA) is encouraging drugmakers to enhance manufacturing capacity and diversify suppliers.There is change visible on the ground. Companies like Midas Pharma, EUROAPI, Seqens are setting up API plants in Europe. Seqens has taken steps to reshore paracetamol production in France and is constructing a new € 100 million (US$ 109 million) production unit in Roussillon. Sanofi is investing €1.3 billion (US$ 1.4 billion) in a new insulin production facility at its existing site in Frankfurt. Similarly, Sandoz has set up a new antibiotic production plant in Austria and a new biosimilar development center in Germany.That said, we know that manufacturing capacities take time to build and are often financially unviable in the developed world. Ergo, a particularly innovative initiative has come from the European Directorate for the Quality of Medicines & HealthCare (EDQM). Their project aims to develop monographs detailing the preparation and testing of unlicensed drugs that can fill the gap left when licensed medicinal products are unavailable. To facilitate this initiative, the European Pharmacopoeia Commission is recruiting experts to verify proposed production methods and analytical procedures.The other means of guarding against supply and demand fluctuations is stockpiling. The EMA has advised the European Commission (EC) and marketing authorization holders (MAH) to stockpile medicines. The regulator has also asked MAHs to establish a shortage prevention plan for critical medicines. Europe’s Health Emergency Response Authority (HERA) is taking a systematic approach to stockpile management.Despite these measures, costs and market structures pose serious challenges. Medicines for Europe, representing the generic and biosimilar medicines industry, has raised concerns about the current market structures. They argue that government purchasing practices, which prioritize obtaining the lowest prices for off-patent medicines, are jeopardizing the European manufacturing footprint and discouraging investments in supply chain resilience.FDA, EMA promote continuous manufacturing; US relies on digital stockpilesDuring the pandemic, there were acute shortages of oncology, cardiovascular, anesthesia, anti-infective, neurological and anti-allergic drugs in the US. A 2022 study undertaken by the Washington University points out that there is excess manufacturing capacity in the US that can be considered for reshoring critical and essential drugs. In fact, 49 percent of generic drug manufacturing capacity in the US is lying idle, and many others are working at less than 50 percent capacity. These capacities can be repurposed. Various advanced manufacturing technologies, such as  “continuous flow and on-demand manufacturing capabilities in idled manufacturing sites offer the ability to reduce production cost,” says this report.FDA has been promoting “advanced manufacturing” technologies, such as continuous manufacturing, which are now a part of America’s overall strategy to strengthen and secure the pharmaceutical supply chain. The EMA has also released guidelines on continuous manufacturing of drug substances and drug products. Advanced manufacturing is a collective term for new or innovative medical product manufacturing technologies. Unlike batch manufacturing, which involves sequential processing and testing of material across multiple discrete stages (and often discrete facilities), continuous manufacturing combines the full manufacturing stream into a single, fully integrated flow. While continuous manufacturing may not be suitable for every drug manufacturing process, but where applicable, it tends to eliminate built-in production gaps and shortens the time taken to manufacture a drug from months to days.In the US, the Strategic National Stockpile (SNS) plays a critical role in ensuring the availability of essential medical supplies during emergencies. It now also involves a digital stockpile that does not store physical goods and products. Instead, it stores electronic plans, instructions, and methods to make and test medical products. Digital stockpiles rely on one or more trusted suppliers that can make the product from the digital information, either through methods like 3D printing or self-contained distributed manufacturing lines.Our viewThe global pharmaceutical supply chain is a complex web spanning multiple countries and continents. While advanced manufacturing and stockpiling may work to an extent, a large chunk of generic drugs and APIs will continue to come from countries like China and India.In order to reduce reliance on China, the US has been proactively expanding its collaboration with India. But this time, there is increased emphasis on quality control. While FDA is increasing the number of inspections at Indian drug plants, the Indian government, on its part, has revised rules for drug manufacturing, with higher GMP standards.Taken together, a multi-pronged approach to addressing supply chain vulnerabilities should secure drug supplies to the US and Europe in the years to come.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5166

    https://www.pharmacompass.com/radio-compass-blog/us-europe-turn-to-advanced-manufacturing-stockpiling-to-strengthen-drug-supply-chains

    #Phispers by PHARMACOMPASS
    17 Oct 2024
    Share Share
    BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans

    BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans

    Over the last two years, there has been a significant surge in layoffs by pharmaceutical and biotech companies. The trend spilled over to 2024. Data compiled by PharmaCompass indicates that between January and early-September, around 150 companies had implemented layoffs. Bristol Myers Squibb (BMS) tops the list of companies that downsized, with a staggering 2,284 job cuts. Bayer stood second at 1,816 retrenchments, followed by Takeda Pharmaceuticals at 1,155. Johnson & Johnson’s spin-off Kenvue is slashing over 1,000 jobs this year, while Roche subsidiary Genentech is cutting 529 positions, and Novartis is going ahead with its multi-year restructuring, and cutting another 770 jobs. One of the primary drivers of layoffs has been the need for companies to streamline operations and reduce costs. Many firms have faced financial pressures due to reasons such as declining revenues, increased competition, and the high costs associated with drug development. The current wave of layoffs has encompassed geographies – from traditional pharma strongholds like New Jersey, biotech hubs in Massachusetts and California, to Europe (particularly Germany and Switzerland). This is not to suggest that job cuts are a norm. Certain segments have been experiencing substantial growth and job creation. This includes companies like Eli Lilly and Novo Nordisk that have experienced remarkable growth due to the efficacy of their glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that treats type 2 diabetes and obesity.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available) BMS cuts 2,284 jobs to meet cost targets, Bayer hands pink slips to 1,816 employees Several large drugmakers have announced job cuts this year in order to meet their cost cutting goals, or as part of their restructuring exercise. BMS’ revenue had declined from US$ 46.2 billion in 2022 to US$ 45 billion in 2023. The financial pressure has compelled it to cut 2,284 jobs so far in this year, a move that sent shockwaves through the industry. Overall, BMS hopes to save approximately US$ 1.5 billion in costs by 2025 through this “strategic productivity initiative”. In Europe, Swiss-based companies like Novartis and Roche have announced substantial job cuts, while Bayer is reducing its workforce globally.  Bayer is laying off 1,816 employees worldwide, including 150 in Basel, Switzerland. A majority of these are management roles as the German drugmaker seeks to target € 500 million (US$ 557 million) in cost savings in 2024 and € 2 billion (US$ 2.23 billion) in 2026. Japanese drugmaker Takeda plans to eliminate 1,155 positions, including 324 jobs in San Diego and 641 in Massachusetts. Takeda is also winding down production and R&D operations in Austria, resulting in 190 job losses. Starting next month, Genentech, a Roche subsidiary, will lay off 93 employees in San Francisco. Earlier this year, Genentech trimmed roughly 3 percent of its workforce across several departments, impacting 436 employees. Roche also laid off around 340 employees in its product development team. Novartis has been undergoing a significant restructuring exercise since 2022, when it announced 8,000 job cuts in its global workforce. This year, it announced an additional 770 job cuts in its product development organization, separate from the previous reductions. Once again, it was workforces in Switzerland (440 job cuts) and US (269 job cuts) that bore the brunt. Tylenol and Band-Aid maker Kenvue, which spun off from J&J last year, announced plans to cut 920 jobs, representing about 4 percent of its global workforce. Additionally, the company will lay off 51 employees in New Jersey and 84 in California. These layoffs are part of Kenvue’s efforts to adjust its cost structure and become more competitive.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Perrigo, Emergent Bio, Catalent, BioMarin trim workforces amid strategic shifts Several mid-size companies too are under tremendous cost pressures, with some of them feeling the need to reinvent themselves for the future. In February this year, Perrigo had embarked on ‘Project Energize’, a three-year initiative aimed at boosting organizational agility and achieving long-term success. As part of this project, Perrigo is cutting costs and laying off 6 percent of its staff, which translates into nearly 550 employees. CDMO-turned-biopharma Emergent BioSolutions plans to reduce its workforce by about 300 employees. The Maryland-based multinational is closing its Baltimore-Bayview drug substance manufacturing facility and its Rockville drug product facility in the state. Rare disease biotech BioMarin laid off 395 employees globally, about 12 percent of its workforce, as part of “organizational redesign efforts” to prioritize its new strategy with its hemophilia A gene therapy Roctavian and to preserve cash. Drug-delivery specialist Catalent has also been significantly impacted by restructuring efforts ever since it announced 1,100 layoffs in December. It had then attributed its fall in revenue to declining Covid-related sales, but had also noted that future GLP-1 manufacturing revenues could help stabilize its finances. True enough — it subsequently announced that it is in the process of being acquired by Novo Nordisk’s parent company for US$ 16.5 billion. However, Catalent reported reducing its headcount by an additional 300 in the fourth quarter of 2023.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Pfizer job cuts continue to trickle in; Lykos, Lyra downsize after pipeline setbacks Clinical trial failures and financial constraints have also played a significant role in this year’s wave of layoffs. At Pfizer, job cuts continued to trickle in, with some estimates putting the number at 1,500 employees in 2024. These include 285 at its vaccine R&D site in New York, and 52 in San Francisco. The Comirnaty maker also pulled the plug on a long-anticipated, near-complete Seagen drug manufacturing plant in Everett, Washington. About 120 employees at the site were let go.  It has been a tumultuous time for Lykos Therapeutics, following the US Food and Drug Administration’s rejection of its MDMA-assisted therapy for post-traumatic stress disorder. Lykos announced laying off 75 percent of its staff (i.e. 75 employees). Its founder, who had spent 38 years working on the therapy, left the company and so did its CEO. However, Lykos has not given up and has roped in a Janssen veteran as senior medical advisor to get the therapy past the finish line. Similarly, Lyra Therapeutics is laying off 75 percent of its workforce (i.e. 87 employees) following disappointing late-stage results for its implant to treat chronic rhino-sinusitis. The retrenchments include its chief technology officer.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Our view Technology, regulatory and pricing pressures are shaping strategies of pharmaceutical companies. The drive to do more with less could accelerate the adoption of artificial intelligence, machine learning, and automation in drug discovery and development processes. The employment landscape is certainly evolving. We foresee significant changes in the skills required for pharmaceutical and biotech careers, with a growing emphasis on data science and computational biology.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4314

    https://www.pharmacompass.com/radio-compass-blog/bms-bayer-takeda-pfizer-downsize-to-combat-cost-pressures-meet-restructuring-plans

    #PharmaFlow by PHARMACOMPASS
    19 Sep 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4729

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share
    FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big

    FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big

    In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molecules. Oligonucleotides are essentially short, single strands of DNA or RNA that modulate gene expression. There are various oligonucleotide therapy (ONT) agents (such as antisense, deoxyribozymes, siRNA and CRISPR/Cas) that offer promising therapeutic tools.A variation of gene therapy, oligonucleotide gene therapies (OGTs) are manufactured using synthetic oligonucleotides. These therapies are designed to enter cells. ONTs act like tools that can fine-tune the behavior of certain genetic instructions, and are therefore often designed to treat rare and genetic diseases and cancers. Sometimes, they may be delivered into cells through lipid nanoparticles or adeno-associated viruses (AAV), halting the translation of a specific protein. Oligonucleotides have also revolutionized vaccine development through the creation of nucleic acid vaccines, such as mRNA vaccines.The first oligonucleotide drug, known as fomivirsen, was approved by the US Food and Drug Administration (FDA) back in 1998. It was developed by Ionis Pharmaceuticals (then known as Isis Pharmaceuticals), and was approved to treat a rare eye disease. However, ONT approvals have picked up since 2016. Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency (EMA) and a majority of them treat orphan and rare diseases.In 2023, FDA approved four ONTs — AstraZeneca-Ionis’ Wainua (eplontersen), Novo Nordisk owned Dicerna Pharmaceuticals’ Rivfloza (nedosiran), Biogen-Ionis’ Qalsody (tofersen) and Iveric Bio’s Izervay (avacincaptad pegol).In 2021, the global ONT market size was estimated to be US$ 18.2 billion. It is expected to increase to US$ 51.4 billion by 2029, growing at a compounded annual rate (CAGR) of 13.85 percent. Similarly, the market for oligonucleotides synthesis (or the process of producing oligonucleotides) was estimated at US$ 7.7 billion globally in 2022 and is expected to grow 11.8 percent CAGR to reach US$ 16.4 billion by 2030. Some of the bigger players in oligonucleotides synthesis are Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins, Agilent, Bio-Synthesis, EUROAPI, Eurogentec, STA Pharma, and Bachem.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available)ONTs address neuro disorders; four ONTs bring in US$ 1.24 bn for AlnylamONTs are widely applied to treat neurodegenerative diseases, such as Duchenne muscular dystrophy (DMD). Multiple ONTs have been approved in Europe and the US for DMD, such as Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Amondys 45 (casimersen) from Sarepta and NS Pharma’s Viltepso (viltolarsen). Last year, Ionis bagged two approvals in the space. FDA approved its Biogen-partnered therapy Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS). The agency also approved AstraZeneca and Ionis’ drug Wainua (eplontersen), rendering it as the first self-administered treatment for a rare nerve damage disease, known as hereditary transthyretin amyloidosis (ATTR-PN). Analysts estimate global peak sales for Wainua to come in at US$ 750 million for ATTR-PN alone. The drug is also being tested for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare heart muscle disorder.Alnylam Pharmaceuticals has also successfully brought four ONTs to market in recent years — Onpattro (patisiran) and Amvuttra (vutrisiran) for rare nerve diseases, and Givlaari (givosiran) and Oxlumo (lumasiran). Givlaari has been approved to treat acute hepatic porphyria (a liver enzyme deficiency) while Oxlumo treats primary hyperoxaluria (a disorder characterized by increased urinary oxalate excretion). The four ONTs brought in US$ 1.24 billion for Alnylam in 2023.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Novartis buys rights to siRNA therapy, GSK bets big on ONT pipeline through dealsAfter Alnylam discovered inclisiran (Leqvio), Novartis acquired global rights to the therapy in a US$ 9.7 billion deal. Leqvio was the first FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction. It brought in US$ 355 million for Novartis in 2023.GSK has increasingly been investing in its ONT pipeline. The British pharma has promised over US$ 5 billion in upfront and milestone payments in multiple deals. In February, GSK exercised its option to license Elsie Biotechnologies’ discovery platform to find and develop novel ONTs. GSK has also entered a discovery collaboration with Wave Life Sciences.Last July, Japanese drugmaker Astellas Pharma completed its approximately US$ 5.9 billion buyout of New Jersey-headquartered Iveric Bio. Iveric focuses on retinal diseases and the deal gives Astellas drug candidates to treat about 160 million people with eye ailments. Subsequently, in August, Iveric’s Izervay (avacincaptad pegol) was approved by the FDA as a new treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).After Novo Nordisk acquired RNAi technology company Dicerna Pharmaceuticals for US$ 3.3 billion in 2021, the latter’s once-monthly RNAi therapy Rivfloza (nedosiran) saw FDA approval last October. Rivfloza was okayed for children nine years and older to treat a rare genetic condition that affects the kidneys, known as primary hyperoxaluria type 1 (PH1).View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Ionis tees up NDAs for rare disease treatments after two late-stage trial winsThe industry is looking for cures to a wide spectrum of diseases like cancer (such as melanoma, pancreatic, liver, glioblastoma, breast and ovarian cancer), cystic fibrosis, Alzheimer’s disease, Parkinson’s disease, hepatitis B, asthma, Rett syndrome, non-alcoholic steatohepatitis, and IgA nephropathy through its research on ONTs.In January, Ionis announced late-stage results wherein its RNA-targeted hereditary angioedema (HAE) candidate, donidalorsen, significantly reduced the rate of HAE attacks in patients treated every four weeks and patients treated every eight weeks. The California-based biotech is readying a new drug application (NDA) to submit to the FDA. HAE is a rare and life-threatening genetic disease that causes unpredictable and frequent severe swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat. This year, Ionis’ olezarsen was granted fast track designation by the FDA for the rare genetic disease familial chylomicronemia syndrome (FCS). Last September, olezarsen had met its primary endpoint of reducing abnormally high levels of triglycerides in a late-stage trial in patients with the metabolic disorder. Currently, there are no FDA-approved treatments for this condition. If okayed, olezarsen is likely to bring in US $849 million in sales for Ionis by 2032.In March, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in certain adult patients with myelodysplastic syndromes. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024, for Geron’s NDA for imetelstat. It is among the most anticipated drug launches this year.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Our viewDeveloping ONTs is a field fraught with challenges, such as toxicity and drug delivery. There are safety concerns as well as concerns around delivering the therapy. However, technological breakthroughs and collaborations between pharma firms and contract research organizations that focus on drug delivery are continuously working towards addressing these challenges. All in all, we foresee exciting times ahead for ONTs.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5616

    https://www.pharmacompass.com/radio-compass-blog/fda-approves-four-oligonucleotide-therapies-in-2023-novartis-gsk-novo-bet-big

    #PharmaFlow by PHARMACOMPASS
    21 Mar 2024
    Share Share

    COMPANY BIO #AboutSupplier

    read-more
    read-more
    Overview of small molecule drug development & contract manufacturing & more on EUROAPI's CDMO services for complex & small molecules on PharmaCompass.
    Overview of small molecule drug development & contract manufacturing & more on EUROAPI's CDMO services for complex & small molecules on PharmaCompass.
    Overview of small molecule drug development & contract manufacturing & more on EUROAPI's CDMO services for complex & small molecules on PharmaCompass.Q1. What are small molecule APIs?Small-molecule APIs are defined as compounds with low...
    #LearnMore
    July, 2022
    Share Share
    Overview of small molecule drug development & contract manufacturing & more on EUROAPI's CDMO services for complex & small molecules on PharmaCompass.

    Overview of small molecule drug development & contract manufacturing & more on EUROAPI's CDMO services for complex & small molecules on PharmaCompass.

    Overview of small molecule drug development & contract manufacturing & more on EUROAPI's CDMO services for complex & small molecules on PharmaCompass.Q1. What are small molecule APIs?Small-molecule APIs are defined as compounds with low molecular weight that are capable of modulating biochemical processes to diagnose, treat or prevent diseases. Small molecules are composed of two or more atoms with a molecular weight of less than 900 Dalton.Active pharmaceutical ingredients (APIs) fall into two main categories - small molecule API and large molecule API. The quality of the active pharmaceutical ingredients depends on the kind of process adopted for manufacture, quality of the starting raw materials, process parameters, solvents used for the extraction, etc.Manufacturing active pharmaceutical ingredients (APIs) is far more complex than manufacturing drug products. However, the quality system that is followed in API manufacturing units is less stringent compared to that of drug product manufacturing.Specialized expertise is needed to achieve success for the production of small molecule APIs, from small-scale clinical development to cGMP commercial manufacturing. The small-molecule API synthesis is a complicated and multi-step process which involves operations with a range of raw materials having different physical and chemical properties.While biologic products are gradually making their presence felt, small molecule API continues to be the cornerstone of pharmaceutical drug development. Rise in demand for effective treatment of chronic diseases has led to an increase in the demand for small molecule APIs. Small-molecule pharmaceuticals accounted for a large number of new drug applications (NDA) and new molecular entities. Further, they represent two-thirds of the drug development pipeline.While the number of large-molecule therapeutics is increasing, small-molecule drugs remain an important and highly effective component of the pharmaceutical portfolio. Large molecules are in much demand for treating cancer and other autoimmune disorders. However, many of the most important drugs introduced in recent years, including kinase inhibitors and anti-retroviral products, are small molecules.There are a lot of challenges associated with the development and manufacturing of small molecule APIs. The manufacturing of small molecule active pharmaceutical ingredients (APIs) can be outsourced to various CDMOs (contract development & manufacturing organizations) and contract manufacturing organizations (CMOs). They can offer various services for small molecule synthesis and manufacturing, drug substance development with pharmaceutical and biotechnology applications for complex, niche and small molecule programs from the preclinical phase to phase 3 clinical development and commercial manufacturing.Q2. What are the advantages of small molecule APIs and what are the steps involved in the development and manufacturing of small molecule APIs?Small molecule drugs have been the mainstay of the pharmaceutical industry for around a century. Rapid advancement of biopharmaceutical research has opened up the possibility for new and innovative approaches to developing small molecule active pharmaceutical ingredients. Small-molecule therapeutics have participated fully in the rapid expansion of drug development activity over the past few years. They have some considerable advantages over large molecules which are noted below:Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics as they can be administered orally, which offer better compliance and a lower cost of administration than injectables.Small molecules can pass through cell membranes to reach intracellular targets, and hence are beneficial for targeted drug delivery.Small molecule drugs can be engineered to deliver a strong therapeutic effect even with a small dose, often below 10 mgs and sometimes in micrograms. The smaller amount of active pharmaceutical ingredient (API) translates into a lower cost for finished products in comparison to large-molecule therapeutics.Small molecule APIs can also be designed to engage biological targets through various modes of action and their distribution can further be tailored.There is a vast amount of formulation expertise and experience with small-molecule drugs, enabling the production of highly controlled formulations that can be delivered to specific sites and released over specific time periods.Small molecules require less cost for construction and maintenance as compared to large molecules. Small-molecule active pharmaceutical ingredient (API) production depends on synthetic chemistry aspects, raw material sourcing and process controls.Clinical trials involving small-molecule therapeutics are often simpler and less expensive than those involving large-molecule drugs.There are various contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) which offer customized API development and manufacturing services. They can provide integrated development and manufacturing services for small molecule drug substances and their intermediates for clinical supplies and commercial manufacturing, depending on the requirement of the customers. Regardless of the breadth of CDMO services offered, CDMOs and contract manufacturing organizations (CMOs) today are seeing a rise in demand for API development and manufacturing services, including solid form selection and particle engineering.Steps involved in small molecule API development and manufacturing are noted below:Route scoutingProcess development and validationClinical batch manufacturingTechnology transfer and process developmentScale-up of established processesProcess validationCommercial small molecule API manufacturingSupply chain managementQ3. How do CDMOs and CMOs help in the production of small molecule APIs?The demand for small molecule drugs remains high and the highly potent small molecule active pharmaceutical ingredients (HPAPIs) segment is growing quickly. However, there are various challenges involved in the development and manufacturing of small molecule APIs. Working with the right contract development and manufacturing organization (CDMO) partners can help address these challenges so that pharmaceutical companies can continue to benefit from small molecule APIs for clinical supplies and commercial manufacturing.In many cases, a contract development and manufacturing organization (CDMO) plays a critical role in facilitating successful drug development of innovator small molecule candidates. Along with small molecule synthesis and manufacturing, a CDMO can also offer drug substance development services. One-third of small molecule API facilities offer containment capabilities, while less than one-tenth offer controlled substance capabilities.Specialist small-molecule active pharmaceutical ingredient (API) capabilities such as containment capabilities and controlled substance capabilities are driving large contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) to acquire facilities for small molecule clinical development and commercial manufacturing. All the top small molecule API CMOs have increased the number of containment facilities for small molecule API manufacturing.A growing number of small and mid-sized pharmaceutical companies developing innovative small-molecule therapeutics are driving the demand for more contract chemical process development and scale-up capacity. These companies often lack in-house laboratory infrastructure and expertise for small molecule drug substance development services.A right CDMO partner can provide small molecule API development services along with process optimization, scale-up and cGMP manufacturing. They can smoothen the transition from laboratory scale small-molecule API synthesis to commercial manufacturing, streamline the process and reduce the complexity.The rise of oncology drugs is a significant growth driver too, as cancer treatments account for a majority of these new approvals. Small molecule HPAPIs offer great therapeutic benefits to patients at low doses, but they require specialized containment procedures. These features are strongly associated with larger contract manufacturing organizations (CMOs), which can afford to develop or acquire these specialist capabilities.High-potency APIs (HPAPIs) are toxic even in small doses. They pose a risk to human health or risk cross-contamination with other drugs in a regular manufacturing environment. Dedicated contract manufacturing organizations (CMOs) are investing heavily in specialist capabilities to meet the growing demand and fulfill the needs for highly potent small molecule development and production.Q4. Which small molecule development and manufacturing services does EUROAPI offer?From over-the-counter (OTC) analgesics to life-saving treatments for cardiovascular (CVS) diseases, small molecule synthesis is critical to the development and effectiveness of a wide range of pharmaceutical therapies. EUROAPI's current synthesis portfolio has about 60 small molecule API references spanning a highly diverse range of therapeutic uses for both humans and animals.Small molecules synthesis and manufacturingEUROAPI is a global leader in small molecules APIs, and its innovation and R&D capabilities enable it to accelerate its contract development and manufacturing organization (CDMO) activities in complex molecule and small-molecule active pharmaceutical ingredient (API) segments.EUROAPI can leverage its illustrious history in API development and small molecule organic synthesis by merging the collective chemical know-how of Hoechst-Aventis, Roussel-Uclaf, Chinoin, Genzyme and Sanofi. One of the biggest API manufacturers in Europe, EUROAPI can offer a full CMC service for any drug substance to support clinical supplies, up to registration and commercial supply.A team of more than 250 scientists work at its six commercial facilities, which can provide 2,000 m³ cGMP for custom organic synthesis and another 6,000 m³ for microbial fermentation for small molecule manufacturing. It has excellent regulatory and quality track records with international health agencies to support registration and commercial production.Around 150 scientists support all aspects of clinical development at its small molecules process development center of excellence located in Ujpest, Budapest. This center is supported by an R&D team located in Frankfurt that focuses on process engineering and flow chemistry, as well as by process industrialization teams in Vertolaye and Frankfurt.

    Impressions: 3078

    NEWS #PharmaBuzz

    read-more
    read-more
    Tristan Imbert Co-Opted As Independent Director
    Tristan Imbert Co-Opted As Independent Director

    10 Dec 2025

    // PRESS RELEASE

    https://www.euroapi.com/en/tristan-imbert-co-opted-as-independent-director

    PRESS RELEASE
    10 Dec 2025
    Share Share
    EUROAPI Boosts Pharmaceutical Innovation With Med4Cure
    EUROAPI Boosts Pharmaceutical Innovation With Med4Cure

    23 Oct 2025

    // PRESS RELEASE

    https://www.euroapi.com/en/with-med4cure-euroapi-accelerates-pharmaceutical-innovation-at-the-service-of-health-sovereignty

    PRESS RELEASE
    23 Oct 2025
    Share Share
    Abolis Bio, EUROAPI Partner to Boost Pharma Innovation in Europe
    Abolis Bio, EUROAPI Partner to Boost Pharma Innovation in Europe

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023325690/en/Abolis-Biotechnologies-and-EUROAPI-Enter-Into-Partnership-to-Accelerate-Pharmaceutical-Innovation-and-Restore-European-Sovereignty

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    Codis Launches as Global CDMO for Commercial Spray Drying
    Codis Launches as Global CDMO for Commercial Spray Drying

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/codis-launches-as-global-cdmo-for-commercial-spray-drying-and-amorphous-solid-dispersions-302580144.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Change In Board's Composition
    Change In Board's Composition

    30 Sep 2025

    // PRESS RELEASE

    https://www.euroapi.com/en/change-in-board-composition

    PRESS RELEASE
    30 Sep 2025
    Share Share
    SBTi Validates EUROAPI's Near-Term Climate Targets
    SBTi Validates EUROAPI's Near-Term Climate Targets

    18 Sep 2025

    // PRESS RELEASE

    https://www.euroapi.com/en/science-based-targets-initiative-sbti-validates-euroapi-near-term-climate-targets

    PRESS RELEASE
    18 Sep 2025
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Alprostadil

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10948

    Submission : 1994-06-20

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2015-302 - Rev 00

    Issue Date : 2022-01-31

    Type : Chemical

    Substance Number : 1488

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 220MF10064

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2008-02-25

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82231-101

    Start Marketing Date : 2014-10-28

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2023-02-02

    Registration Number : 20230202-210-J-1440

    Manufacturer Name : EUROAPI Hungary Ltd.

    Manufacturer Address : To utca 1-5., Budapest, 1045, Hungary

     VMF CN arrow-down
    ✖
    Available Reg. Filing : CN
    AUDIT arrow-down
    EUROAPI Compnay Banner

    02

    Clobazam

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-02-27

    Pay. Date : 2013-02-13

    DMF Number : 18340

    Submission : 2005-05-09

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2004-314 - Rev 01

    Issue Date : 2022-02-08

    Type : Chemical

    Substance Number : 1974

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10337

    Registrant's Address : Brueningstrasse 50, 65926 Frankfurt am Main, Germany

    Initial Date of Registration : 2006-03-09

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82348-103

    Start Marketing Date : 2020-07-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT arrow-down
    EUROAPI Compnay Banner

    03

    Dexamethasone

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-09-28

    Pay. Date : 2013-09-18

    DMF Number : 1748

    Submission : 1971-06-21

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 1996-019 - Rev 09

    Issue Date : 2024-04-12

    Type : Chemical

    Substance Number : 388

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10376

    Registrant's Address : 15 rue Traversie(')re 75012 Paris France

    Initial Date of Registration : 2006-03-20

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82298-110

    Start Marketing Date : 2011-02-07

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : AbbVie Korea Co., Ltd.

    Registration Date : 2023-07-03

    Registration Number : 20230405-209-J-1469(A)

    Manufacturer Name : EUROAPI France

    Manufacturer Address : 4 La Paterie, Vertolaye, 63480, France

     VMF Others AUDIT arrow-down
    EUROAPI Compnay Banner

    04

    Hydrocortisone

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 2789

    Submission : 1976-11-11

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2012-163 - Rev 01

    Issue Date : 2021-12-16

    Type : Chemical

    Substance Number : 335

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 220MF10093

    Registrant's Address : 15 rue Traversie(')re 75012 Paris France

    Initial Date of Registration : 2008-03-28

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82298-101

    Start Marketing Date : 2011-02-07

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Novartis Korea Co., Ltd.

    Registration Date : 2023-07-25

    Registration Number : 20230725-209-J-1524

    Manufacturer Name : EUROAPI France

    Manufacturer Address : 4 Lieu Dit La Paterie, Vertolaye, 63480, France

     VMF ASMF arrow-down
    ✖
    Available Reg. Filing : ASMF
    AUDIT arrow-down
    EUROAPI Compnay Banner

    05

    Hydrocortisone

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-08-04

    Pay. Date : 2016-04-08

    DMF Number : 30373

    Submission : 2016-03-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2019-166 - Rev 03

    Issue Date : 2024-11-25

    Type : Chemical

    Substance Number : 335

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 228MF10090

    Registrant's Address : 15 rue Traversie(')re 75012 Paris France

    Initial Date of Registration : 2016-04-15

    Latest Date of Registration :

    EU-WC NDC KDMF VMF ASMF arrow-down
    ✖
    Available Reg. Filing : ASMF
    AUDIT arrow-down
    EUROAPI Compnay Banner

    06

    Hydroxocobalamin Acetate

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-03-04

    Pay. Date : 2013-02-27

    DMF Number : 16152

    Submission : 2002-09-25

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2001-179 - Rev 10

    Issue Date : 2025-10-07

    Type : Chemical

    Substance Number : 913

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10374

    Registrant's Address : 82 Avenue Raspail 94250 Gentilly France

    Initial Date of Registration : 2006-03-20

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82298-920

    Start Marketing Date : 2015-02-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT arrow-down
    EUROAPI Compnay Banner

    07

    Ketoprofen

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-02-14

    Pay. Date : 2013-02-13

    DMF Number : 23600

    Submission : 2010-03-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2009-340 - Rev 02

    Issue Date : 2021-12-09

    Type : Chemical

    Substance Number : 922

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 222MF10169

    Registrant's Address : Brueningstrasse 50, 65926 Frankfurt am Main, Germany

    Initial Date of Registration : 2010-06-08

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82348-102

    Start Marketing Date : 2010-07-27

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT arrow-down
    EUROAPI Compnay Banner

    08

    Latanoprost

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-09-11

    Pay. Date : 2013-01-16

    DMF Number : 26728

    Submission : 2012-12-14

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2021-352 - Rev 00

    Issue Date : 2022-12-02

    Type : Chemical

    Substance Number : 2230

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 225MF10111

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2013-05-30

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Samil Pharmaceutical Co., Ltd.

    Registration Date : 2022-10-18

    Registration Number : 20221018-211-J-1382

    Manufacturer Name : EUROAPI Hungary Ltd.

    Manufacturer Address : To utca 1-5., Budapest, 1045, Hungary

     VMF ASMF arrow-down
    ✖
    Available Reg. Filing : ASMF
    AUDIT arrow-down
    EUROAPI Compnay Banner

    09

    Methylprednisolone Hemisuccinate

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-01-14

    Pay. Date : 2014-01-06

    DMF Number : 2922

    Submission : 1977-05-02

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2005-228 - Rev 03

    Issue Date : 2021-12-17

    Type : Chemical

    Substance Number : 1131

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 220MF10128

    Registrant's Address : 82 Avenue Raspail 94250 Gentilly France

    Initial Date of Registration : 2008-05-15

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 82298-109

    Start Marketing Date : 2011-02-07

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF ASMF arrow-down
    ✖
    Available Reg. Filing : ASMF
    AUDIT arrow-down
    EUROAPI Compnay Banner

    10

    Naloxone Hydrochloride

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-02-15

    Pay. Date : 2013-01-23

    DMF Number : 23142

    Submission : 2009-09-30

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 1996-050 - Rev 08

    Issue Date : 2025-10-20

    Type : Chemical

    Substance Number : 729

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10971

    Registrant's Address : 82 Avenue Raspail 94250 Gentilly France

    Initial Date of Registration : 2006-12-01

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Korea Mundipharma Co., Ltd.

    Registration Date : 2013-06-14

    Registration Number : 20130507-176-I-164-01(1)

    Manufacturer Name : Sanofi Winthrop Industrie

    Manufacturer Address : Route d'Avignon 30390 Aramon France

     VMF CN arrow-down
    ✖
    Available Reg. Filing : CN
    AUDIT arrow-down
    EUROAPI Compnay Banner
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Alprostadil

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : R1-CEP 2015-302 - Rev 00

    Status : Valid

    Issue Date : 2022-01-31

    Type : Chemical

    Substance Number : 1488

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Apomorphine hydrochloride hemihydrate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : CEP 2008-332 - Rev 05

    Status : Valid

    Issue Date : 2025-11-21

    Type : Chemical

    Substance Number : 136

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Clobazam

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : R1-CEP 2004-314 - Rev 01

    Status : Valid

    Issue Date : 2022-02-08

    Type : Chemical

    Substance Number : 1974

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Clobazam, Micronised

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : R1-CEP 2016-281 - Rev 00

    Status : Valid

    Issue Date : 2022-02-16

    Type : Chemical

    Substance Number : 1974

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Codeine monohydrate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : CEP 2014-143 - Rev 03

    Status : Valid

    Issue Date : 2025-10-20

    Type : Chemical

    Substance Number : 76

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Codeine phosphate hemihydrate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : CEP 1997-118 - Rev 13

    Status : Valid

    Issue Date : 2025-10-20

    Type : Chemical

    Substance Number : 74

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Cyanocobalamin

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : R1-CEP 1998-140 - Rev 05

    Status : Valid

    Issue Date : 2021-12-13

    Type : Chemical

    Substance Number : 547

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Cyanocobalamin, 200 µm grade

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : R1-CEP 2015-361 - Rev 01

    Status : Valid

    Issue Date : 2021-12-13

    Type : Chemical

    Substance Number : 547

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Dexamethasone acetate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : CEP 1998-089 - Rev 08

    Status : Valid

    Issue Date : 2025-01-22

    Type : Chemical

    Substance Number : 548

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Dexamethasone sodium phosphate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Certificate Numbers : R2-CEP 1992-014 - Rev 07

    Status : Valid

    Issue Date : 2021-12-16

    Type : Chemical

    Substance Number : 549

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Acetic acid hydroxocobalamin

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 218MF10374

    Registrant's Address : 82 Avenue Raspail 94250 Gentilly France

    Initial Date of Registration : 2006-03-20

    Latest Date of Registration : 2013-10-09

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Alprostadil

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 220MF10064

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2008-02-25

    Latest Date of Registration : 2016-12-20

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Alprostadil alfadex

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 218MF10339

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2006-05-22

    Latest Date of Registration : 2010-01-07

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Beraprost sodium

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 218MF10340

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2006-03-09

    Latest Date of Registration : 2012-07-09

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Beraprost Sodium

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 303MF10151

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2021-09-17

    Latest Date of Registration : 2021-09-17

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Bimatoprost

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 229MF10098

    Registrant's Address : To(´) utca 1-5. , 1045 Budapest, Hungary

    Initial Date of Registration : 2017-05-24

    Latest Date of Registration : 2017-05-24

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Clobazam

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 218MF10337

    Registrant's Address : Brueningstrasse 50, 65926 Frankfurt am Main, Germany

    Initial Date of Registration : 2006-03-09

    Latest Date of Registration : 2010-01-07

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Clopidogrel sulfate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 226MF10008

    Registrant's Address : 82 Avenue Raspail 94250 Gentilly (FRANCE)

    Initial Date of Registration : 2014-01-08

    Latest Date of Registration : 2015-04-09

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Cortisone acetate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 222MF10121

    Registrant's Address : 82 Avenue Raspail 94250 Gentilly France

    Initial Date of Registration : 2010-04-02

    Latest Date of Registration : 2020-02-06

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Cyanocobalamin

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EUROAPI

    Registration Number : 222MF10011

    Registrant's Address : 15 rue Traversie(')re 75012 Paris France

    Initial Date of Registration : 2010-01-07

    Latest Date of Registration : 2024-02-07

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    alprostadil

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2023-02-02

    Registration Number : 20230202-210-J-1440

    Manufacturer Name : EUROAPI Hungary Ltd.

    Manufacturer Address : To utca 1-5., Budapest, 1045, Hungary

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    02

    Amisulpiride

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Sanofi-Aventis Korea Co., Ltd.

    Registration Date : 2022-09-22

    Registration Number : 20220922-209-J-1388

    Manufacturer Name : Sanofi Winthrop Industrie

    Manufacturer Address : 45 Chemin De Météline, Sisteron, 04200, France

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    03

    beraprost sodium

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Shin Poong Pharmaceutical Co., Ltd.

    Registration Date : 2024-09-04

    Registration Number : 20210609-209-J-1017(1)

    Manufacturer Name : EUROAPI Hungary Ltd.

    Manufacturer Address : To utca 1-5., Budapest, 1045, Hungary

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    04

    beraprost sodium

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2021-06-09

    Registration Number : 20210609-209-J-1017

    Manufacturer Name : EUROAPI Hungary Ltd.

    Manufacturer Address : To utca 1-5., Budapest, 1045, Hungary

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    05

    Clopidogrel sulfate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Handok Co., Ltd.

    Registration Date : 2010-11-30

    Registration Number : 20101130-129-H-39-07

    Manufacturer Name : Sanofi Winthrop Industrie

    Manufacturer Address : 45 Chemin De Météline, Sisteron, 04200, France

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    06

    codeine phosphate monohydrate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Nosa Chemical Co., Ltd.

    Registration Date : 2020-06-16

    Registration Number : 20200616-209-J-616

    Manufacturer Name : Saneca Pharmaceuticals as

    Manufacturer Address : Nitrianska 100, 920 27 Hlohovec, Slovak Republic

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    07

    Dexamethasone

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : AbbVie Korea Co., Ltd.

    Registration Date : 2023-07-03

    Registration Number : 20230405-209-J-1469(A)

    Manufacturer Name : EUROAPI France

    Manufacturer Address : 4 La Paterie, Vertolaye, 63480, France

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    08

    Dexamethasone

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Novartis Korea Co., Ltd.

    Registration Date : 2023-04-05

    Registration Number : 20230405-209-J-1469

    Manufacturer Name : EUROAPI France

    Manufacturer Address : 4 Lieu Dit La Paterie, Vertolaye, 63480, France

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    09

    Dexamethasone disodium phosphate

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Bashu Health Korea Co., Ltd.

    Registration Date : 2023-01-06

    Registration Number : 20230106-209-J-1432

    Manufacturer Name : EUROAPI France

    Manufacturer Address : 4 La Paterie, 63480 VERTOLAYE, France

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    10

    Dinoprostone

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Registrant Name : Korea Ferring Pharmaceutical Co., Ltd.

    Registration Date : 2022-11-02

    Registration Number : 20221102-209-J-1396

    Manufacturer Name : EUROAPI Hungary Ltd.

    Manufacturer Address : To u. 1-5., Budapest, 1045, Hungary

    EUROAPI Compnay Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

    Details:

    The collaboration aims to support Protheria for the development and manufacturing KRP203 (mocravimod), which is being evaluated in the late-stage for the treatment of adult acute myeloid leukemia.


    Lead Product(s): Mocravimod,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Priothera

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 18, 2024

    EUROAPI Compnay Banner

    01

    EUROAPI

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Lead Product(s) : Mocravimod,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Priothera

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

    Details : The collaboration aims to support Protheria for the development and manufacturing KRP203 (mocravimod), which is being evaluated in the late-stage for the treatment of adult acute myeloid leukemia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    June 18, 2024

    EUROAPI Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    CDMO: EUROAPI Supports Sanofi’s mRNA Vaccine Platform with The Development of Lipid Nanoparticles

    Details:

    EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi’s mRNA vaccines platform, targeting indications including Flu.


    Lead Product(s): mRNA Vaccine,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Vaccine

    Sponsor: Sanofi

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration May 30, 2022

    EUROAPI Compnay Banner

    02

    EUROAPI

    France
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Lead Product(s) : mRNA Vaccine,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    CDMO: EUROAPI Supports Sanofi’s mRNA Vaccine Platform with The Development of Lipid Nanoparticle...

    Details : EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi’s mRNA vaccines platform, targeting indications including Flu.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    May 30, 2022

    EUROAPI Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ALL Intermediates

    read-more
    read-more
    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    2-Methoxyl-4-amino-5- ethylsulfonylbenzoic acid

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    71675-87-1
    Amisulpride
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    01

    2-Methoxyl-4-amino-5- ethylsulfonylbenzoic acid

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    2-Methoxyl-4-amino-5- ethylsulfonylbenzoic acid

    CAS Number : 71675-87-1

    End Use API : Amisulpride

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    2-(2-thienyl)ethylamine

    Intermediate Web Link

    Market Place

    30433-91-1
    Clopidogrel
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    02

    2-(2-thienyl)ethylamine

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    2-(2-thienyl)ethylamine

    CAS Number : 30433-91-1

    End Use API : Clopidogrel

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    2-(4-aminopentyl(ethyl)amino)ethanol

    Intermediate Web Link

    Market Place

    69559-11-1
    Hydroxychloroquine Sulphate
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    03

    2-(4-aminopentyl(ethyl)amino)ethanol

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    2-(4-aminopentyl(ethyl)amino)ethanol

    CAS Number : 69559-11-1

    End Use API : Hydroxychloroquine Sulphate

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)- 4-phenyl-5-oxazolid...

    Intermediate Web Link

    Market Place

    196404-55-4
    Docetaxel
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    04

    (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)- 4-phenyl-5-oxazolidinecarboxylic acid

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)- 4-phenyl-5-oxazolid...

    CAS Number : 196404-55-4

    End Use API : Docetaxel

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)- 4-phenyl-5-oxazolid...

    Intermediate Web Link

    Market Place

    196404-55-4
    Paclitaxel
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    05

    (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)- 4-phenyl-5-oxazolidinecarboxylic acid

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)- 4-phenyl-5-oxazolid...

    CAS Number : 196404-55-4

    End Use API : Paclitaxel

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    21-hydroxypregna-1,4,9(11),16-tetraene3,20-dione-21-acetate De...

    Intermediate Web Link

    Market Place

    37413-91-5
    Dexamethasone
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    06

    21-hydroxypregna-1,4,9(11),16-tetraene3,20-dione-21-acetate Decortidiene

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    21-hydroxypregna-1,4,9(11),16-tetraene3,20-dione-21-acetate De...

    CAS Number : 37413-91-5

    End Use API : Dexamethasone

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Noroxymorphone

    Intermediate Web Link

    Market Place

    33522-95-1
    Naltrexone
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    07

    Noroxymorphone

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Noroxymorphone

    CAS Number : 33522-95-1

    End Use API : Naltrexone

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Erythromycine Oxime

    Intermediate Web Link

    Market Place

    13127-18-9
    Erythromycin
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    08

    Erythromycine Oxime

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Erythromycine Oxime

    CAS Number : 13127-18-9

    End Use API : Erythromycin

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Erythromycine Oxime

    Intermediate Web Link

    Market Place

    13127-18-9
    Tylosin
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    09

    Erythromycine Oxime

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Erythromycine Oxime

    CAS Number : 13127-18-9

    End Use API : Tylosin

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Ethyl 2-(4-(2,2-dichlorocyclopropyl) phenoxy)-2-methylpropiona...

    Intermediate Web Link

    Market Place

    52179-28-9
    Ciprofibrate
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and pat...
    EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our CDMO activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
    EUROAPI Compnay Banner

    10

    Ethyl 2-(4-(2,2-dichlorocyclopropyl) phenoxy)-2-methylpropionate

    France
    Global ChemShow
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    EUROAPI

    Ethyl 2-(4-(2,2-dichlorocyclopropyl) phenoxy)-2-methylpropiona...

    CAS Number : 52179-28-9

    End Use API : Ciprofibrate

    About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sust...

    EUROAPI Compnay Banner

    Intermediate Web Link

    Market Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    Biologics, Bioprocess & Fermentation

    read-more
    read-more

    01

    MICROBIAL FERMENTATION

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI offers CDMO services for microbial fermentation. It is a global provider of high-quality custom microbial process development and manufacturing for all pharmaceutical and biotech companies.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    MICROBIAL FERMENTATION

    EUROAPI offers CDMO services for microbial fermentation. It is a global provider of high-quality custom microbial process development and manufacturing for all pharmaceutical and biotech companies.

    arrow
    Microbial Fermentation

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    02

    MICROBIAL FERMENTATION (YEAST & BACTERIA...

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI is a global provider of high-quality custom microbial process development and manufacturing. Both of its fermentation manufacturing sites enjoy long-standing, successful regulatory track records and operate under cGMP regulations & FDA approval.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    MICROBIAL FERMENTATION (YEAST & BACTERIA)

    EUROAPI is a global provider of high-quality custom microbial process development and manufacturing. Both of its fermentation manufacturing sites enjoy long-standing, successful regulatory track records and operate under cGMP regulations & FDA approval.

    arrow
    Microbial Fermentation (Yeast, Bacteria)

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    03

    SMALL MOLECULE MICROBIAL FERMENTATION

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI offers CDMO services for microbial fermentation. It has six commercial facilities offering 2,000 m³ cGMP for organic synthesis and 6,000 m³ for microbial fermentation to produce small molecules.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    SMALL MOLECULE MICROBIAL FERMENTATION

    EUROAPI offers CDMO services for microbial fermentation. It has six commercial facilities offering 2,000 m³ cGMP for organic synthesis and 6,000 m³ for microbial fermentation to produce small molecules.

    arrow
    Small Molecule Microbial Fermentation

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    04

    FERMENTATION BIOTECH CDMO

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI is a global provider of high-quality custom microbial process development and manufacturing for all pharmaceutical and biotech companies. Its expertise spans a wide range of GMO and non-GMO microorganisms in 6,000m³ of fermentation capacity.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    FERMENTATION BIOTECH CDMO

    EUROAPI is a global provider of high-quality custom microbial process development and manufacturing for all pharmaceutical and biotech companies. Its expertise spans a wide range of GMO and non-GMO microorganisms in 6,000m³ of fermentation capacity.

    arrow
    Fermentation Biotech CDMO

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    05

    API MICROBIAL FERMENTATION

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI offers CDMO services for microbial fermentation. It has the capability for pilot and industrial-scale fermentation and serves as a global provider of high-quality custom microbial process development and manufacturing.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    API MICROBIAL FERMENTATION

    EUROAPI offers CDMO services for microbial fermentation. It has the capability for pilot and industrial-scale fermentation and serves as a global provider of high-quality custom microbial process development and manufacturing.

    arrow
    API Microbial Fermentation

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    06

    MICROBIAL FERMENTATION CMO

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI offers CDMO services for microbial fermentation. From proteins and enzymes to yeasts and actinomycetes, EUROAPI’s expertise spans a wide range of GMO and non-GMO microorganisms procured from its fermentation facilities in France and Italy.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    MICROBIAL FERMENTATION CMO

    EUROAPI offers CDMO services for microbial fermentation. From proteins and enzymes to yeasts and actinomycetes, EUROAPI’s expertise spans a wide range of GMO and non-GMO microorganisms procured from its fermentation facilities in France and Italy.

    arrow
    Microbial Fermentation Contract Manufacturing

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    07

    CONTRACT MANUFACTURER FOR FERMENTATION

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI is a CDMO with six commercial facilities, offering 2,000 m³ cGMP for organic synthesis and 6,000 m³ for microbial fermentation to produce small molecules.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    CONTRACT MANUFACTURER FOR FERMENTATION

    EUROAPI is a CDMO with six commercial facilities, offering 2,000 m³ cGMP for organic synthesis and 6,000 m³ for microbial fermentation to produce small molecules.

    arrow
    Contract Manufacturer for Fermentation

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    08

    CDMO FOR INDUSTRIAL FERMENTATION

    France
    Contact Supplier
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    EUROAPI

    EUROAPI is a CDMO that offers industrial fermentation services. It is a global provider of high-quality custom microbial process development and manufacturing for biotech and pharmaceutical companies.

    arrow

    Category : Biologics, Bioprocess & Fermentation

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Pharma Service : API Manufacturing

    CDMO FOR INDUSTRIAL FERMENTATION

    EUROAPI is a CDMO that offers industrial fermentation services. It is a global provider of high-quality custom microbial process development and manufacturing for biotech and pharmaceutical companies.

    arrow
    CDMO for Industrial Fermentation Services

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    EUROAPI VB Popup full-view
    Oligosaccharide API Development
    full-view
    Purification & Isolation Technologies
    full-view
    Steroid / Hormone API Development
    full-view
    Microbial Fermentation
    full-view
    Hazardous Chemistry services
    full-view
    Oligosaccharides Manufacturing
    full-view
    Organometallic Chemistry
    full-view
    Organometallic Chemistry
    full-view
    Extraction & Isolation Technology
    full-view
    Small Molecule API Contract Manufacturing
    full-view

    Excipients

    Discover the DDS // excipients from this company

    Excipients by Ingredients

    Discover their expertise by components

    Excipients By applications

    Discover their expertise by claims

    Inspections and registrations

    Check the inspections & registration from this company

    THIRD-PARTY AUDIT

    read-more
    read-more

    01

    Eurofins Assurance

    Belgium
    arrow
    Get Site Audit
    CPhI Milan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

    EUROAPI

    Country : France

    City/Region : Vertolaye

    Audit Date : 2026-11-19

    Audit Type : On-Site

    Eurofins Assurance

    02

    Eurofins Assurance

    Belgium
    arrow
    Get Site Audit
    CPhI Milan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

    EUROAPI

    Country : France

    City/Region : Saint Aubin Les Elbeuf

    Audit Date : 2025-05-20

    Audit Type : On-Site

    Eurofins Assurance

    03

    Eurofins Assurance

    Belgium
    arrow
    Get Site Audit
    CPhI Milan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

    EUROAPI

    Country : Italy

    City/Region : Brindisi

    Audit Date : 2024-03-13

    Audit Type : On-Site

    Eurofins Assurance

    04

    Eurofins Assurance

    Belgium
    arrow
    Get Site Audit
    CPhI Milan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

    EUROAPI

    Country : Germany

    City/Region : Frankfurt am Main

    Audit Date : 2024-02-20

    Audit Type : On-Site

    Eurofins Assurance

    05

    Eurofins Assurance

    Belgium
    arrow
    Get Site Audit
    CPhI Milan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

    EUROAPI

    Country : France

    City/Region : Vertolaye

    Audit Date : 2023-11-23

    Audit Type : On-Site

    Eurofins Assurance

    06

    Eurofins Assurance

    Belgium
    arrow
    Get Site Audit
    CPhI Milan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEurofins Assurance: Ensuring compliance, quality, and safety with expert inspection and certification.

    EUROAPI

    Country : France

    City/Region : Aramon

    Audit Date : Planned

    Audit Type : On-Site

    Eurofins Assurance
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact SANOFI Active Ingredient Solutions and get a quotation

    SANOFI Active Ingredient Solutions is a supplier offers 141 products (APIs, Excipients or Intermediates).

    Find a price of Alprostadil bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Clobazam bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Dexamethasone bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Dexamethasone Sodium Phosphate bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Hydrocortisone bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Hydroxocobalamin Acetate bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Ketoprofen bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Latanoprost bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Methylprednisolone Hemisuccinate bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Naloxone Hydrochloride bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisolone bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisolone Acetate bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Selegiline Hydrochloride bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Spironolactone bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Vitamin B12 bulk with DMF, CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Apomorphine Hydrochloride bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Bimatoprost bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Dexamethasone bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Dinoprostone bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Fexofenadine Hydrochloride bulk with CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Fluorometholone bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Fluticasone Propionate bulk with CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Glimepiride bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Hydrocortisone Acetate bulk with CEP, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Hydroxocobalamin bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Irbesartan bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Methylprednisolone bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Naltrexone Hydrochloride bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisone bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Ramipril bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Rifampicin bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Rifaximin bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Sevelamer Hydrochloride bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Sodium Cromoglicate bulk with DMF, CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Travoprost bulk with DMF, JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Alprostadil Alfadex bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Beraprost Sodium bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Bimatoprost bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Carboprost Tromethamine bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Clobazam bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Clopidogrel bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Codeine bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Codeine Phosphate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Cortisone bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Desoximetasone bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Dexamethasone Sodium Phosphate bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Dinoprost bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Dinoprost Tromethamine bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Epoprostenol Sodium bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Ethylmorphine Hydrochloride bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Glimepiride bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Hydrocortisone bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Hydrocortisone Acetate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Hydrocortisone Sodium Succinate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Hydroxocobalamin Acetate bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Hydroxocobalamin Hydrochloride bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Hydroxychloroquine Sulphate bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Iloprost bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Levomepromazine Hydrochloride bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Levomepromazine Maleate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Levomethadone bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Limaprost Alfadex bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Morphine Hydrochloride bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Morphine Sulfate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Nalbuphine Hydrochloride bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Norepinephrine bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Norepinephrine Bitartrate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Oxycodone Hydrochloride bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Piretanide bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Prednicarbate bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisolone bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Ramipril bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Teicoplanin bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Tiaprofenic Acid bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Treprostinil Sodium bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Triamcinolone Acetonide bulk with DMF offered by SANOFI Active Ingredient Solutions

    Find a price of Vitamin B12 bulk with CEP offered by SANOFI Active Ingredient Solutions

    Find a price of Zolpidem Tartrate bulk with JDMF offered by SANOFI Active Ingredient Solutions

    Find a price of Alimemazine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Altrenogest bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Amiodarone Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Amisulpride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Buprenorphine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Buprenorphine Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Canrenoate Potassium bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Chlorpromazine Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Clonazepam bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Cloprostenol Sodium bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Codeine Sulfate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Cyamemazine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Cyamemazine Tartrate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Dalbavancin bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Daptomycin bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Dexamethasone bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Dinoprost Tromethamine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Divalproex Sodium bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Drotaverine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Eflornithine Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Enoxaparin Sodium bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Epinephrine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Epinephrine Bitartrate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Fexinidazole bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Fidaxomicin bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Fluorometholone bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Fluticasone Furoate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Furosemide bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Hydrocortisone Valerate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Hydroxychloroquine Sulphate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Inclisiran bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Insulin bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Irbesartan bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Loprazolam Mesilate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Lubiprostone bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Meglumine Antimonate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Methylprednisolone Acetate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Misoprostol bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Nadolol bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Naloxone Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Nedocromil Sodium bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Noscapine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Olmesartan Medoxomil bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Oxymorphone bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisolone bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisolone Acetate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Prednisolone Sodium Metasulfobenzoate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Promethazine Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Ramipril bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Rifamycin Sodium bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Rifapentine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Riluzole bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Roxithromycin bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Selegiline Hydrochloride bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Sevelamer Carbonate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Sodium Valproate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Tafluprost bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Trenbolone Acetate bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Treprostinil Diolamine bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Tulathromycin bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Vitamin B12 bulk offered by SANOFI Active Ingredient Solutions

    Find a price of Zopiclone bulk offered by SANOFI Active Ingredient Solutions

    Find a price of MANUFACTURING OPERATIONS bulk offered by SANOFI Active Ingredient Solutions

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search